This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hepatomegaly is a medical term for an enlarged liver. It is usually a symptom of another underlying medical condition, such as cirrhosis, hepatitis, or fatty liver disease. It can also be caused by other conditions, such as certain medications, alcoholism, genetic disorders, and non-alcoholic fatty liver disease. The symptoms of hepatomegaly vary depending on the underlying cause. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). In some cases, a doctor may be able to detect an enlarged liver by physical examination. In other cases, an imaging test such as an ultrasound or computed tomography (CT) scan may be necessary to confirm the diagnosis. Treatment for hepatomegaly depends on the underlying cause. In some cases, such as with viral hepatitis, medications can be used to treat the virus and reduce the size of the liver. In other cases, lifestyle changes, such as weight loss and exercise, may be recommended to reduce fat in the liver and improve overall health. In cases of liver cirrhosis and other serious conditions, a liver transplant may be necessary to save the patient’s life. It is important to see a doctor if you have any symptoms associated with hepatomegaly. A doctor can help determine the underlying cause and recommend the best course of treatment, which may include lifestyle changes, medications, or surgery. Early diagnosis and treatment can help reduce the risk of complications and may even save your life.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States